Corvus Pharmaceuticals announced new interim data on January 13, 2025, from Cohort 2 of the randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. This update includes 28-day follow-up data for 10 patients from Cohort 2 (200 mg orally once per day), alongside previously reported Cohort 1 results.
For the combined 19 patients in the soquelitinib treatment groups across Cohorts 1 and 2, 26% achieved IGA 0 or 1 and 37% achieved EASI 75. In contrast, none of the seven patients in the placebo group achieved these clinically meaningful endpoints, which are recognized by the FDA for regulatory approval.
The data from Cohort 2 demonstrated improved efficacy compared to Cohort 1, with clinically meaningful activity observed in key endpoints. Soquelitinib continued to show a favorable safety profile, with no significant safety issues or clinically significant laboratory abnormalities reported across all patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.